See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy

Publications for Miriam Kimpton

Updated daily

Back to Member List

#	PubMedId	Deleted	Publication
	39442625	0	Anuku D, Carrier M, Le Gal G, et al. Impact of limited language proficiency on participation in venous thromboembolism research: A retrospective analysis. J Thromb Haemost. 2024 Oct 21:S1538-7836(24)00562-2. doi: 10.1016/j.jtha.2024.09.014.
	38927943	0	Xu Y, Carrier M, Kimpton M. Arterial Thrombosis in Patients with Cancer. Cancers (Basel). 2024 Jun 17;16(12):2238. doi: 10.3390/cancers16122238.
	37196605	0	Wang TF, Carrier M, Carney BJ, et al. Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: A systematic review and meta-analysis. Thromb Res. 2023 May 11;227:8-16. doi: 10.1016/j.thromres.2023.05.012.
	35040802	0	Kimpton M, Kumar S, Wells PS, et al. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. CMAJ. 2021 Oct 12;193(40):E1551-E1560. doi: 10.1503/cmaj.210523.
	34516270	0	Khan F, Tritschler T, Kimpton M, et al. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 Oct;174(10):1420-1429. doi: 10.7326/M21-1094. Epub 2021 Sep 14.
	34379859	0	Khan F, Tritschler T, Kimpton M, et al. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 Nov;19(11):2801-2813. doi: 10.1111/jth.15491. Epub 2021 Aug 22.
	32539500	0	Kimpton M, Rodger MA. Web Exclusive. Annals for Hospitalists Inpatient Notes - Can I Withdraw Anticoagulants in This Patient With Prior Venous Thromboembolism? Ann Intern Med. 2020 Jun 16;172(12):HO2-HO3. doi: 10.7326/M20-1253.
	31808858	0	Kimpton M, Carrier M. What's new in the prevention and treatment of cancer-associated thrombosis? Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):158-166. doi: 10.1182/hematology.2019000023.
	31808849	0	Kimpton M, Siegal DM. Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):204-208. doi: 10.1182/hematology.2019000074.
	31661033	0	Khan F, Kimpton M, Tritschler T, et al. Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol. Syst Rev. 2019 Oct 28;8(1):245. doi: 10.1186/s13643-019-1175-5.
	30925842	0	Kimpton M, Carrier M. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. Expert Opin Drug Saf. 2019 Apr;18(4):313-320. doi: 10.1080/14740338.2019.1601699. Epub 2019 Apr 8.
	29703470	0	Kimpton M, Wells PS, Carrier M. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. Thromb Res. 2018 Apr;164 Suppl 1:S124-S129. doi: 10.1016/j.thromres.2018.01.018.